In advanced-stage NSCLC, therapies that target genetic alterations have been shown to be effective, especially for those with EGFR mutations, EGFR-TKIs, and for those with EML4-ALK mutations, an ALK inhibitor (such as crizotinib). This evidence concerns the gene ALK and non-small cell lung carcinoma.